Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.

Trial Profile

Phase I/II study of HB-EGF-specific inhibitor BK-UM plus weekly paclitaxel therapy in gastric cancer with peritoneal metastasis after failure of first line treatment.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2016

At a glance

  • Drugs CRM 197 (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2016 Status changed from suspended to discontinued.
    • 07 Dec 2015 Status changed from recruiting to suspended, as reported by University Hospital Medical Information Network - Japan.
    • 19 Mar 2015 Status changed from not yet recruiting to recruiting, according to University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top